Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-19T13:15:50.395Z Has data issue: false hasContentIssue false

The Effects of Cyclosporine on Protein Expression of P53 and Transforming Growth Factor-Beta in Human Renal Tubular Cells

Published online by Cambridge University Press:  02 July 2020

H. Song
Affiliation:
Cardiorenal Molecular Research, Departments of Surgery and Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201
C. Wei
Affiliation:
Cardiorenal Molecular Research, Departments of Surgery and Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201
Get access

Extract

Cyclosporine-A (CsA) is the widely used immunosuppressant drug in renal transplantation. However, the effects of cyclosporine-A are limited by a significant nephrotoxicity. The mechanisms of CsA-induced allograft nephropathy are remaining controversial. Recent study indicated that cellular apoptosis may contribute to the cyclosporine A-mediated cytotoxic action. To date, regarding the effects of cyclosporine A on renal cell apoptosis-related gene expression remain poorly defined. p53 is an important gene in control of renal cell growth and death. Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that has anti-proliferative as well as fibrogenic properties.

We hypothesized that cyclosporine-A may increase p53 and TGF-β expression in renal tubular cells. These actions of cyclosporine-A may contribute to the cellular apoptosis, fibrosis and CsA-induced nephrotoxicity. Therefore, current study was designed to determine the effects of cyclosporine-A on the p53 and TGF-βl protein expression by immunohistochemical staining (IHCS) in cultured human tubular cells.

Type
Pathology
Copyright
Copyright © Microscopy Society of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References:

1.Oberbauer, R., et al. J Am Soc Nephrol. (1999) 10, 20062013.Google Scholar
2.Chandraker, A., et al. J Clin Invest (1998) 101, 2039–2018.CrossRefGoogle Scholar
3.Wever, P. C., et al. Clin Nephrol (1998) 49, 2834.Google Scholar
4.Ferrandiz, C., et al. Br J Dermatol (1996) 134, 810811.CrossRefGoogle Scholar
5. This research was supported in part by grants from the NIH (HL03174 & HL61299, C Wei), AHAMD, NKF and University of Maryland School of Medicine.Google Scholar